CYP2D6 Activity Assay, Catalog: MA-0221

Catalog MA-0221

Size 200 wells

Sample Type Human liver microsomes and liver S9 fractions, Lysates of tissues and cultured cells, primary hepatocytes, Heterologously expressed recombinant CYP2D6 preparations

Method of Detection Fluorometric, Ex/Em = 406/468 nm

Assay Type Quantitative

Application A simple, sensitive means of assessing CYP2D6 activity levels in a variety of biological samples.

Storage Conditions -20°C

Shipping Temperature Gel Pack

Shelf Life One year from the date of delivery

CYP2D6. A member of the P450 superfamily, is responsible for the oxidative metabolism of around 25% of clinically significant drugs. As with other members of the P450 family it is susceptible to genetic polymorphism which results is a wide range of enzyme activities from very slow to extremely rapid which can affect the dosage necessary for the proper pharmacological benefit. Some important drugs metabolized by this isoform include the painkiller, codeine which is transformed into morphine. Poor metabolizers can experience insufficient pain relief while rapid metabolizers can develop opioid toxicity from the same dose. Tamoxifen, used to treat breast cancer is transformed into its more active form, endoxifen by CYP2D6, so poor metabolizers can have inadequate drug levels leading to poor therapeutic outcomes. Pharmacogenetic testing for the activity of CYP2D6 is thus, an important, yet not yet, widely used screen to adjust drug dosages to the individual’s need. AkrivisBio’s CYP2D6 is a simple, sensitive means of determining CYP2D6 activity levels from biological samples.